Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

PMID:
30045932
2.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
3.

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.

Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P.

Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.

4.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

5.

A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball M, Negus S, Bruce MG, Morishima C, Knall C, McMahon BJ.

J Infect Dis. 2016 Jul 15;214(2):273-80. doi: 10.1093/infdis/jiw142. Epub 2016 Apr 7.

6.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.

7.

Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection.

Yu L, Morishima C, Ioannou GN.

Br J Nutr. 2016 Jan 28;115(2):193-201. doi: 10.1017/S0007114515004158. Epub 2015 Nov 6.

PMID:
26541123
8.

Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial.

Yu L, Morishima C, Ioannou GN.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1661-6.e1-3. doi: 10.1016/j.cgh.2013.05.018. Epub 2013 May 23.

PMID:
23707779
9.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

10.

Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.

Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group.

J Viral Hepat. 2012 Jun;19(6):404-13. doi: 10.1111/j.1365-2893.2011.01562.x. Epub 2011 Dec 16.

11.

A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses.

Polyak SJ, Morishima C, Scott JD, Gastaminza P, Cox A, de Araújo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr.

Gastroenterology. 2012 Jan;142(1):e1-5. doi: 10.1053/j.gastro.2011.11.002. No abstract available. Erratum in: Gastroenterology. 2012 Feb;142(2):411. Gastaminza, Pablo [added].

PMID:
22185796
12.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

13.

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group.

Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169.

14.

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group.

Gastroenterology. 2011 May;140(5):1490-500.e3. doi: 10.1053/j.gastro.2011.01.053. Epub 2011 Feb 15.

15.

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.

Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ.

PLoS One. 2011 Jan 28;6(1):e16464. doi: 10.1371/journal.pone.0016464.

16.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group.

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

17.

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group.

Aliment Pharmacol Ther. 2011 Jan;33(1):127-37. doi: 10.1111/j.1365-2036.2010.04503.x. Epub 2010 Nov 2.

18.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group.

Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744.

19.

Identification of hepatoprotective flavonolignans from silymarin.

Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5995-9. doi: 10.1073/pnas.0914009107. Epub 2010 Mar 15.

20.

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ; HALT-C Trial Group.

Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315.

Supplemental Content

Loading ...
Support Center